热门资讯> 正文

scPharmaceuticals获得涵盖SCP-111的多项美国专利申请的许可通知

2025-08-14 22:29

scPharmaceuticals (NASDAQ:SCPH) has received five notices of allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering their latest furosemide formulation, SCP-111.
The SCP-111 formulation is the subject of a supplemental NDA expected to be filed by the Company this quarter.
The five patents, once issued, will join four additional patents owned by the Company that cover the SCP-111 formulation.

More on scPharmaceuticals

scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript
scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025
ScPharmaceuticals anticipates meaningful Q3 nephrology contribution as FUROSCIX shipments rise 45% in Q2 2025
Seeking Alpha’s Quant Rating on scPharmaceuticals
Historical earnings data for scPharmaceuticals

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。